Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Research Associate, Cell Therapy Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Oct 21, 2021

View more

Job Details

Why Join Intellia? 

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. 

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. 

We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.   

How you will Achieve More with Intellia:

We are excited to welcome a new Senior Research Associate to the Cell Therapy Process Development team. In this position, you can expect to work closely with current scientists, associate scientists, and process engineers in the group to get hands-on training on key instrumentation and our T cell engineering process. We are responsible for the characterization and optimization of Intellia’s growing portfolio of ex vivo cell therapy products.

In your role, you will lead projects, design experiments, collect and analyze data, and present your findings to the larger group. Specific areas of focus for this position include the characterization and optimization of our cell culture and expansion media formulations to ensure a robust T cell engineering process that produces the best product possible. Using a range of bioanalytical assays, you will assess the effects of various media components such as basal media, serum proteins, and cytokines on T cell gene editing, expansion, and phenotype. You will also be responsible for evaluating the stability of media components in different storage conditions and comparing the effectiveness of components from different sources. Working with other members of the group, you will also be involved in maintaining adequate stock of media components and assisting in forecasting usage of consumables in our process over time. 

About You:

  • Bachelor’s or Master’s Degree in Biology, Biochemistry, or equivalent

  • Experienced in mammalian cell culture and aseptic technique

  • Broad experience in bioanalytical techniques including analysis of cells and biomolecules

  • Familiar with immunology and concepts concerning T cell function and differentiation

  • Strong writing skills with experience in writing SOPs and technical reports

  • Ability to communicate effectively and thrive in a team with time-critical objectives 

Meet your future team:

The Cell Therapy Process Development team is a rapidly growing group of six motivated scientists and engineers. We work in collaboration with our colleagues in research, analytical development, and other process development groups. We meet regularly to discuss data and share scientific discoveries and literature. In our group discussions, everyone is encouraged to ask questions and share their insights into the process. You will report to a Scientist and work closely with other Associate Scientists, Process Engineers, and Research Associates.

#LI-KO1

Covid-19 Vaccination Policy: Effective Monday, January 3, 2022, all Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert